LFA Lugano Financial Advisors SA purchased a new position in Humana Inc (NYSE:HUM) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 690 shares of the insurance provider’s stock, valued at approximately $204,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of HUM. Raymond James Trust N.A. boosted its position in shares of Humana by 19.8% during the 2nd quarter. Raymond James Trust N.A. now owns 956 shares of the insurance provider’s stock valued at $284,000 after acquiring an additional 158 shares in the last quarter. Trust Co boosted its position in shares of Humana by 7.7% during the 1st quarter. Trust Co now owns 2,326 shares of the insurance provider’s stock valued at $625,000 after acquiring an additional 167 shares in the last quarter. Daiwa SB Investments Ltd. boosted its position in shares of Humana by 27.9% during the 2nd quarter. Daiwa SB Investments Ltd. now owns 780 shares of the insurance provider’s stock valued at $232,000 after acquiring an additional 170 shares in the last quarter. Advisor Partners LLC boosted its position in shares of Humana by 5.3% during the 2nd quarter. Advisor Partners LLC now owns 3,604 shares of the insurance provider’s stock valued at $1,073,000 after acquiring an additional 180 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. boosted its position in shares of Humana by 1.7% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 11,901 shares of the insurance provider’s stock valued at $3,541,000 after acquiring an additional 197 shares in the last quarter. Institutional investors own 92.99% of the company’s stock.

Shares of NYSE HUM traded down $1.56 during trading on Friday, reaching $318.35. The company had a trading volume of 796,621 shares, compared to its average volume of 755,712. Humana Inc has a 52 week low of $231.90 and a 52 week high of $341.30. The company has a market cap of $46.64 billion, a PE ratio of 27.19, a P/E/G ratio of 1.69 and a beta of 0.97. The company has a current ratio of 1.43, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, August 1st. The insurance provider reported $3.96 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.79 by $0.17. Humana had a net margin of 2.48% and a return on equity of 17.43%. The company had revenue of $14.26 billion during the quarter, compared to the consensus estimate of $14.16 billion. During the same period in the previous year, the firm posted $3.49 earnings per share. As a group, equities research analysts forecast that Humana Inc will post 14.18 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, October 26th. Shareholders of record on Friday, September 28th will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 0.63%. The ex-dividend date is Thursday, September 27th. Humana’s dividend payout ratio is presently 17.08%.

Several analysts have recently weighed in on HUM shares. Bank of America lifted their target price on shares of Humana from $338.00 to $375.00 and gave the company a “buy” rating in a research report on Thursday, August 2nd. Zacks Investment Research upgraded shares of Humana from a “hold” rating to a “buy” rating and set a $377.00 price target on the stock in a research report on Thursday, October 4th. Piper Jaffray Companies boosted their price target on shares of Humana from $326.00 to $350.00 and gave the company an “overweight” rating in a research report on Friday, July 6th. ValuEngine upgraded shares of Humana from a “hold” rating to a “buy” rating in a research report on Wednesday, July 4th. Finally, BMO Capital Markets boosted their price target on shares of Humana from $328.00 to $355.00 and gave the company an “outperform” rating in a research report on Monday, June 25th. Seven analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $339.79.

In related news, CEO Bruce D. Broussard sold 18,000 shares of the business’s stock in a transaction that occurred on Monday, September 10th. The shares were sold at an average price of $328.66, for a total transaction of $5,915,880.00. Following the completion of the sale, the chief executive officer now directly owns 71,085 shares of the company’s stock, valued at $23,362,796.10. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Cynthia H. Zipperle sold 4,886 shares of the business’s stock in a transaction that occurred on Friday, August 3rd. The stock was sold at an average price of $321.89, for a total transaction of $1,572,754.54. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 40,284 shares of company stock valued at $13,147,715. Insiders own 0.60% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.

Featured Story: Average Daily Trade Volume – What It Means In Stock Trading

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.